Cipla shares in focus after receiving CDSCO nod to launch inhalation insulin

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for managing type 1 and type 2 diabetes. Clinical trials in India demonstrated its effectiveness in reducing HbA1c levels. Cipla aims to improve diabetes management accessibility with this innovative treatment.